Applied Dna Sciences Inc (NASDAQ:APDN) Institutional Investors Quarterly Sentiment

Applied DNA Sciences, Inc. (NASDAQ:APDN) Logo

Sentiment for Applied Dna Sciences Inc (NASDAQ:APDN)

Applied Dna Sciences Inc (NASDAQ:APDN) institutional sentiment decreased to 0.57 in 2019 Q2. Its down -0.43, from 1 in 2019Q1. The ratio dropped, as 4 active investment managers started new or increased holdings, while 7 sold and trimmed equity positions in Applied Dna Sciences Inc. The active investment managers in our partner’s database now possess: 2.08 million shares, up from 2.00 million shares in 2019Q1. Also, the number of active investment managers holding Applied Dna Sciences Inc in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 3 Increased: 0 New Position: 4.

Applied DNA Sciences, Inc. provides biotechnology based security solutions for supply chain security, brand protection, and law enforcement applications in the United States, Europe, and Asia. The company has market cap of $9.80 million. The company’s supply chain security and product authentication solutions include SigNature DNA markers that are ingredients used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNature T DNA markers, which are tagging and authentication systems for use in brand protection efforts and raw material source compliance programs; and fiberTyping, a test of native cotton fiber. It currently has negative earnings. It also provides DNAnet, a DNA marker to link evidence and offenders to specific crime scenes; Beacon locked optical markers are encrypted mechanisms, which create a protected covert screening tool that can be adapted to packaging, security labels, and high–value assets through inks, varnishes, and coatings; and SigNify IF portable DNA reader that provides real-time authentication of in the field–DNA.

The stock decreased 12.45% or $0.029 during the last trading session, reaching $0.204. About 350,767 shares traded. Applied DNA Sciences, Inc. (NASDAQ:APDN) has declined 78.55% since October 12, 2018 and is downtrending. It has underperformed by 78.55% the S&P500.

Chase Investment Counsel Corp holds 0.07% of its portfolio in Applied DNA Sciences, Inc. for 261,163 shares. Bank Of America Corp De owns 3,057 shares or 0% of their US portfolio. Moreover, Blackrock Inc. has 0% invested in the company for 158,367 shares. The California-based California Public Employees Retirement System has invested 0% in the stock. Capital Investment Advisors Llc, a Georgia-based fund reported 53,500 shares.

More notable recent Applied DNA Sciences, Inc. (NASDAQ:APDN) news were published by: Seekingalpha.com which released: “Applied DNA: 90+% Downside On Fraud Partners, Opaque U.K. Shell Deal And Paid Stock Promotion – Seeking Alpha” on October 29, 2015, also Seekingalpha.com with their article: “Applied DNA -11% after filing to offer shares – Seeking Alpha” published on September 18, 2019, Businesswire.com published: “Applied DNA Subsidiary LineaRx Licenses CAR T Drug Candidate and Initiates Pre-Clinical Development of Non-Viral, Plasmid-Free CAR T Manufacturing Platform – Business Wire” on October 16, 2018. More interesting news about Applied DNA Sciences, Inc. (NASDAQ:APDN) were released by: Businesswire.com and their article: “Applied DNA Subsidiary, LineaRx, Inc. Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer Vaccines – Business Wire” published on September 20, 2018 as well as Businesswire.com‘s news article titled: “Applied DNA and GHCL Launch “REKOOP” Verified by the CertainT Platform on Amazon.com on Earth Day – Business Wire” with publication date: April 22, 2019.

Applied DNA Sciences, Inc. (NASDAQ:APDN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.